Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701622 · ClinicalTrials.gov registry record · NA
The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
A NA study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01701622: Clinical Trial NA study, sponsored by University of Mississippi Medical Center.
NCT01701622 is a NA study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01701622, a NA study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Hyperuricemia (high uric acid level) has been correlated to hypertension (high blood pressure) and overall cardiovascular disease risk in several studies. The relationship has even been noted to be independent of metabolic syndrome and kidney function. It has been repeatedly noted that hyperuricemia was an independent risk factor of death in those at high cardiovascular disease risk. A recent review concluded that there is strong evidence that hyperuricemia and gout are coupled with atherosclerosis and cardiovascular events. Although this correlation of hypertension and hyperuricemia is known, there has only been one published study that has evaluated if lowering the uric acid would reduce the blood pressure. The authors concluded that in newly diagnosed hypertensive adolescents, allopurinol decreased the blood pressure. Despite this, further evaluation of this therapeutic approach has not been studied. The hypothesis of this study is that febuxostat, a new xanthine oxidase inhibitor, has blood pressure lowering effects superior to allopurinol in patients diagnosed with gout.
Primary Outcome
The data collected will be analyzed and categorized according to age, race, gender, weight, height, 24-hour ABPM (24-hour systolic blood pressure (SBP)/diastolic blood pressure (DBP), trough SBP/DBP, and the mean nighttime SBP/SBP). Clinic systolic and diastolic BP and 24-hour AMBPs will be compared between the two treatments.
Interventions
- DRUG febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-10 |
| Phase | NA |
Why NCT01701622 stopped before completion
NCT01701622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which febuxostat is the first listed.
NCT01701622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01701622 about?
NCT01701622 is a clinical study titled "The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study". Hyperuricemia (high uric acid level) has been correlated to hypertension (high blood pressure) and overall cardiovascular disease risk in several studies. The relationship has even been noted to be independent of metabolic syndrome and kidney function. It has been repeatedly noted that hyperuricemia...
What is the current status of trial NCT01701622?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2010-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01701622?
The interventions under investigation include: febuxostat (DRUG).
Who is sponsoring clinical trial NCT01701622?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01701622's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia